MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-17-2026
Enochian Biosciences Operating Expenses 2011-2026 | ENOB
Annual Operating Expenses Enochian Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 189 M | 81.6 M | 38.6 M | 116 M | 23.4 M | 11.9 M | 11 M | 8.17 M | 2.65 M | 2.16 M | 2.67 M | 2.13 M | 37.1 K | 29.9 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 189 M | 29.9 K | 35 M |
Quarterly Operating Expenses Enochian Biosciences
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.82 M | 3.31 M | - | 4.16 M | 4.55 M | 53.3 M | - | 51.4 M | 4.27 M | 8.88 M | - | 4.06 M | 4.37 M | 7.19 M | - | 4.03 M | - | - | - | 3.05 M | 3.31 M | 2.86 M | 6.16 M | 3.83 M | 2.82 M | 2.44 M | 2.82 M | 2.44 M | 4.38 M | 1.81 M | 6.27 M | 3.77 M | 1.28 M | 626 K | 1.28 M | 626 K | 549 K | 852 K | 549 K | 852 K | 632 K | 341 K | 632 K | 341 K | 865 K | 370 K | 504 K | 394 K | - | 324 K | 1.66 M | 197 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 53.3 M | 197 K | 4.78 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.07 B | $ 9.33 | 1.41 % | $ 603 M |  USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.87 | -2.13 % | $ 6.4 M | China |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.38 | 0.81 % | $ 3.71 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Galapagos NV
GLPG
|
709 M | $ 28.15 | 1.04 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
1.64 B | $ 8.22 | 3.92 % | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
462 M | $ 30.95 | -0.34 % | $ 1.78 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
ImmuCell Corporation
ICCC
|
9.8 M | $ 8.43 | -0.12 % | $ 76.1 M | USA |
 |
InflaRx N.V.
IFRX
|
52.4 M | $ 1.97 | -0.51 % | $ 152 M | Germany |
 |
Incyte Corporation
INCY
|
1.62 B | $ 98.55 | -0.55 % | $ 19.2 B | USA |
 |
InMed Pharmaceuticals
INM
|
9.78 M | $ 0.71 | 1.27 % | $ 1.74 M |  Canada |
 |
Innoviva
INVA
|
144 M | $ 22.97 | -0.35 % | $ 1.55 B | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 104.02 | 2.41 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Jaguar Health
JAGX
|
36 M | $ 7.34 | -6.79 % | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
161 M | $ 26.68 | 0.02 % | $ 1.44 B | Britain |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
63 M | $ 1.45 | -2.68 % | $ 235 M | France |
 |
Kamada Ltd.
KMDA
|
69 K | $ 8.16 | 0.68 % | $ 260 M |  Israel |
 |
Krystal Biotech
KRYS
|
228 M | $ 260.24 | 0.11 % | $ 7.53 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
8.82 M | $ 13.58 | 9.34 % | $ 1.8 B |  Australia |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
115 M | $ 220.06 | -2.13 % | $ 4.02 B | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 2.94 | -1.67 % | $ 4.84 M | Israel |
 |
Liquidia Corporation
LQDA
|
59.6 | $ 38.41 | 0.67 % | $ 3.31 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.08 | 0.62 % | $ 436 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 23.15 | 3.49 % | $ 2.95 B | USA |